Technical Analysis for SNGX - Soligenix, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 0.39 | 0.67% | 0.00 |
SNGX closed up 0.67 percent on Friday, May 17, 2024, on 5 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: May 21
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Resistance | Bearish | 0.00% | |
Bollinger Band Squeeze | Range Contraction | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Jack-in-the-Box Bearish | Bearish Swing Setup | 0.67% | |
Bollinger Band Squeeze | Range Contraction | 0.67% | |
BB Squeeze + Lower Band Touch | Range Contraction | 0.67% | |
Inside Day | Range Contraction | 0.67% | |
Lower Bollinger Band Touch | Weakness | 0.67% | |
New 52 Week Closing Low | Bearish | 8.01% |
Alert | Time |
---|---|
Rose Above Previous Day's High | 1 day ago |
Up 1% | 1 day ago |
Rose Above Lower Bollinger Band | 3 days ago |
Up 5% | 3 days ago |
Up 3% | 3 days ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/21/2024
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases where, as well as developing several biodefense vaccines and therapeutics. The Company operates in two reportable segments: BioTherapeutics and BioDefense. The BioTherapeutics business segment intends to develop orBec ' (oral beclomethasone dipropionate, or oral BDP) and other biotherapeutic products, including LPM TM Leuprolide. The BioDefense business segment intends to convert its ricin toxin vaccine and radiation injury programs from early stage development to advanced development and manufacturing. Soligenix, Inc, formerly known as DOR BioPharma, Inc, is headquartered in Princeton, New Jersey.
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Cancer Treatment Gastrointestinal Radiation Therapeutic Products Toxins Proteins Biodefense Biological Warfare Gastrointestinal Disease Lectins Biotherapeutic Products
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Cancer Treatment Gastrointestinal Radiation Therapeutic Products Toxins Proteins Biodefense Biological Warfare Gastrointestinal Disease Lectins Biotherapeutic Products
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 2.0 |
52 Week Low | 0.3609 |
Average Volume | 3,322,492 |
200-Day Moving Average | 0.56 |
50-Day Moving Average | 0.50 |
20-Day Moving Average | 0.40 |
10-Day Moving Average | 0.40 |
Average True Range | 0.04 |
RSI (14) | 41.18 |
ADX | 23.15 |
+DI | 21.70 |
-DI | 18.85 |
Chandelier Exit (Long, 3 ATRs) | 0.35 |
Chandelier Exit (Short, 3 ATRs) | 0.48 |
Upper Bollinger Bands | 0.43 |
Lower Bollinger Band | 0.37 |
Percent B (%b) | 0.37 |
BandWidth | 13.36 |
MACD Line | -0.03 |
MACD Signal Line | -0.03 |
MACD Histogram | 0.0054 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.41 | ||||
Resistance 3 (R3) | 0.41 | 0.41 | 0.41 | ||
Resistance 2 (R2) | 0.41 | 0.40 | 0.41 | 0.41 | |
Resistance 1 (R1) | 0.40 | 0.40 | 0.40 | 0.40 | 0.41 |
Pivot Point | 0.39 | 0.39 | 0.39 | 0.39 | 0.39 |
Support 1 (S1) | 0.39 | 0.39 | 0.38 | 0.39 | 0.38 |
Support 2 (S2) | 0.38 | 0.38 | 0.38 | 0.38 | |
Support 3 (S3) | 0.37 | 0.38 | 0.37 | ||
Support 4 (S4) | 0.37 |